Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01877382
Title A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Daiichi Sankyo Inc.


Advanced Solid Tumor


Milademetan Tosylate

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Karmanos Cancer Institute Detroit Michigan 48201 United States Details
Columbia University College of Physicians and Surgeons New York New York 10032 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
Tennessee Oncology Nashville Tennessee 37203 United States Details
UT MD Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from for the field